Published in Neurobiol Dis on November 01, 2005
The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J (2008) 2.43
Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J (2007) 2.12
Prion protein attenuates excitotoxicity by inhibiting NMDA receptors. J Cell Biol (2008) 2.10
The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta (2007) 2.09
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
The prion protein knockout mouse: a phenotype under challenge. Prion (2007) 1.51
The CNS glycoprotein Shadoo has PrP(C)-like protective properties and displays reduced levels in prion infections. EMBO J (2007) 1.49
Prion Protein Protects against Renal Ischemia/Reperfusion Injury. PLoS One (2015) 1.39
The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol (2007) 1.25
Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J (2008) 1.18
Prion neurotoxicity: insights from prion protein mutants. Curr Issues Mol Biol (2009) 1.02
Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med (Berl) (2009) 0.99
Prion protein with an octapeptide insertion has impaired neuroprotective activity in transgenic mice. EMBO J (2007) 0.98
Fishing for prion protein function. PLoS Biol (2009) 0.97
Transport of prion protein across the blood-brain barrier. Exp Neurol (2009) 0.95
Context dependent neuroprotective properties of prion protein (PrP). Prion (2009) 0.95
Redox control of prion and disease pathogenesis. Antioxid Redox Signal (2010) 0.93
Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. Antioxid Redox Signal (2015) 0.90
Cellular prion protein and NMDA receptor modulation: protecting against excitotoxicity. Front Cell Dev Biol (2014) 0.87
Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7-PSD-95 binding. Mol Biol Cell (2011) 0.86
Signal transducers and activators of transcription: STATs-mediated mitochondrial neuroprotection. Antioxid Redox Signal (2011) 0.86
Neuroprotective effects of bilobalide on cerebral ischemia and reperfusion injury are associated with inhibition of pro-inflammatory mediator production and down-regulation of JNK1/2 and p38 MAPK activation. J Neuroinflammation (2014) 0.86
Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis. Am J Pathol (2010) 0.86
Is, indeed, the prion protein a Harlequin servant of "many" masters? Prion (2009) 0.84
Gene regulatory network analysis supports inflammation as a key neurodegeneration process in prion disease. BMC Syst Biol (2012) 0.84
The prion protein is critical for DNA repair and cell survival after genotoxic stress. Nucleic Acids Res (2014) 0.82
Cellular prion protein (PrP(C)) and its role in stress responses. Int J Clin Exp Med (2015) 0.81
Detection and control of prion diseases in food animals. ISRN Vet Sci (2012) 0.80
Neuroprotective effects of the cellular prion protein in autoimmune optic neuritis. Am J Pathol (2011) 0.80
Cellular prion protein promotes post-ischemic neuronal survival, angioneurogenesis and enhances neural progenitor cell homing via proteasome inhibition. Cell Death Dis (2015) 0.80
Role of prions in neuroprotection and neurodegeneration: a mechanism involving glutamate receptors? Prion (2009) 0.78
Identification of bilateral changes in TID1 expression in the 6-OHDA rat model of Parkinson's disease. PLoS One (2011) 0.78
Translation of the prion protein mRNA is robust in astrocytes but does not amplify during reactive astrocytosis in the mouse brain. PLoS One (2014) 0.78
Reply to Altered Monoaminergic Systems and Depressive-like Behavior in Congenic Prion Protein Knock-out Mice. J Biol Chem (2015) 0.77
NCAM1 Polysialylation: The Prion Protein's Elusive Reason for Being? ASN Neuro (2016) 0.77
Deficiency of prion protein induces impaired autophagic flux in neurons. Front Aging Neurosci (2014) 0.77
Reduction of PrP(C) in human cerebrospinal fluid after spinal cord injury. Prion (2010) 0.77
Behavioral abnormalities in prion protein knockout mice and the potential relevance of PrP(C) for the cytoskeleton. Prion (2014) 0.77
Primary blast-induced traumatic brain injury in rats leads to increased prion protein in plasma: a potential biomarker for blast-induced traumatic brain injury. J Neurotrauma (2015) 0.76
The Cellular Prion Protein: A Player in Immunological Quiescence. Front Immunol (2015) 0.76
Prion protein as a mediator of synaptic transmission. Commun Integr Biol (2015) 0.75
The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules. Front Mol Neurosci (2017) 0.75
Physiological Functions of the Cellular Prion Protein. Front Mol Biosci (2017) 0.75
Tauroursodeoxycholic acid reduces ER stress by regulating of Akt-dependent cellular prion protein. Sci Rep (2016) 0.75
Neuroprotective properties of the PrP-like Shadoo glycoprotein assessed in the middle cerebral artery occlusion model of ischemia. Prion (2015) 0.75
A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease. Prion (2016) 0.75
Prions: Beyond a Single Protein. Clin Microbiol Rev (2016) 0.75
Air quality, stroke, and coronary events: results of the Heinz Nixdorf Recall Study from the Ruhr Region. Dtsch Arztebl Int (2015) 2.10
Sleep-disordered breathing and periodic limb movements in narcolepsy with cataplexy: a systematic analysis of 35 consecutive patients. Eur Neurol (2013) 2.05
Serum paraoxonase 1 activity and oxidative stress in pediatric patients with pulmonary tuberculosis. Med Princ Pract (2014) 1.99
Violence in sleep. Brain (2010) 1.92
Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain (2009) 1.89
Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice. EMBO J (2005) 1.83
Validation of the fatigue severity scale in a Swiss cohort. Sleep (2008) 1.72
Sleep-wake disturbances 3 years after traumatic brain injury. J Neurol Neurosurg Psychiatry (2010) 1.71
VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain (2004) 1.67
The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J (2006) 1.64
Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study. Brain (2007) 1.64
Loss of hypocretin (orexin) neurons with traumatic brain injury. Ann Neurol (2009) 1.54
TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol Dis (2008) 1.52
Sleep homeostasis in the rat is preserved during chronic sleep restriction. Proc Natl Acad Sci U S A (2010) 1.49
Effects of sleep fragmentation on the arousability to resistive loading in NREM and REM sleep in normal men. Sleep (2006) 1.48
Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB J (2005) 1.40
Sleep-related breathing and sleep-wake disturbances in ischemic stroke. Neurology (2009) 1.39
Neural stem/precursor cells for the treatment of ischemic stroke. J Neurol Sci (2007) 1.31
Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci (2006) 1.31
Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity. Brain (2011) 1.29
Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J (2004) 1.25
The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res (2004) 1.24
Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy. Brain (2007) 1.24
Characteristic CSF prion seeding efficiency in humans with prion diseases. Mol Neurobiol (2014) 1.19
Animal models of ischemic stroke. Part two: modeling cerebral ischemia. Open Neurol J (2010) 1.18
Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol (2012) 1.14
MicroRNA-124 protects against focal cerebral ischemia via mechanisms involving Usp14-dependent REST degradation. Acta Neuropathol (2013) 1.13
Bovine tuberculosis in Europe from the perspective of an officially tuberculosis free country: trade, surveillance and diagnostics. Vet Microbiol (2011) 1.13
Morphological differences in Parkinson's disease with and without rest tremor. J Neurol (2009) 1.12
Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci (2006) 1.10
Endothelial dysfunction and arterial stiffness in ischemic stroke: the role of sleep-disordered breathing. Stroke (2013) 1.08
Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for neuroprotection. BMC Genomics (2008) 1.08
c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation (2008) 1.08
Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain (2010) 1.07
Abnormal activity in reward brain circuits in human narcolepsy with cataplexy. Ann Neurol (2010) 1.07
PrP(CWD) lymphoid cell targets in early and advanced chronic wasting disease of mule deer. J Gen Virol (2002) 1.07
Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol Cell Neurosci (2002) 1.06
Evolution of neurological, neuropsychological and sleep-wake disturbances after paramedian thalamic stroke. Stroke (2007) 1.06
Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res (2005) 1.06
When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) (2005) 1.06
Hypocretins (orexins) and sleep-wake disorders. Lancet Neurol (2005) 1.06
Role of Nogo-A in neuronal survival in the reperfused ischemic brain. J Cereb Blood Flow Metab (2010) 1.06
Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice. J Pineal Res (2008) 1.05
Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice. Ann Neurol (2002) 1.04
Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke (2003) 1.04
Vascular endothelial growth factor induces contralesional corticobulbar plasticity and functional neurological recovery in the ischemic brain. Acta Neuropathol (2011) 1.04
Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res Bull (2008) 1.02
Total dream loss: a distinct neuropsychological dysfunction after bilateral PCA stroke. Ann Neurol (2004) 1.02
Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: therapeutic potential against ischemic stroke after intrastriatal and systemic transplantation. Stem Cells (2012) 1.02
Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med (2004) 1.02
Melatonin suppresses cisplatin-induced nephrotoxicity via activation of Nrf-2/HO-1 pathway. Nutr Metab (Lond) (2013) 1.02
Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep Med (2009) 1.01
Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. J Mol Biol (2002) 1.00
Spongiform encephalopathy in transgenic mice expressing a point mutation in the β2-α2 loop of the prion protein. J Neurosci (2011) 0.99
The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis. Brain (2012) 0.99
Longitudinal polysomnographic assessment from acute to subacute phase in infratentorial versus supratentorial stroke. Cerebrovasc Dis (2014) 0.98
Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal (2010) 0.98
Standard procedures for adults in accredited sleep medicine centres in Europe. J Sleep Res (2011) 0.97
Evidence for metabolic hypothalamo-amygdala dysfunction in narcolepsy. Sleep (2009) 0.97
Pseudocataplexy in narcolepsy with cataplexy. Sleep Med (2010) 0.96
Sleep EEG changes after middle cerebral artery infarcts in mice: different effects of striatal and cortical lesions. Sleep (2006) 0.96
English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gélineau in the late 19th century, with commentary. J Clin Sleep Med (2007) 0.95
Challenging sleep homeostasis in narcolepsy-cataplexy: implications for non-REM and REM sleep regulation. Sleep (2008) 0.95
Insufficient non-REM sleep intensity in narcolepsy-cataplexy. Sleep (2007) 0.95
Increased balloon-induced inflammation, proliferation, and neointima formation in apolipoprotein E (ApoE) knockout mice. Stroke (2006) 0.94